Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

• Glavni autori: Thomas Monfeuga (Autor), Jenny Norlin (Autor), Anne Bugge (Autor), Elisabeth D. Gaalsgaard (Autor), Cesar A. Prada-Medina (Autor), Markus Latta (Autor), Sanne S. Veidal (Autor), Pia S. Petersen (Autor), Michael Feigh (Autor), Dorte Holst (Autor)
• Format: Knjiga
• Izdano: Elsevier, 2024-01-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Objective: The metabolic benefits of GLP-1 receptor (GLP-1R) agonists on glycemic and weight control are well established as therapy for type 2 diabetes and obesity. Glucagon's ability to increase energy expenditure is well described, and the combination of these mechanisms-of-actions has the p...